Scarica l'app Stockscreener
97.82
3.13%
-3.16
Dopo l'orario di chiusura:
97.50
-0.32
-0.33%
Precedente Chiudi:
$100.98
Aprire:
$99.85
Volume 24 ore:
797.54K
Relative Volume:
0.84
Capitalizzazione di mercato:
$3.81B
Reddito:
$117.67M
Utile/perdita netta:
$-1.88B
Rapporto P/E:
-1.6159
EPS:
-60.5369
Flusso di cassa netto:
$-621.36M
1 W Prestazione:
-6.75%
1M Prestazione:
+14.68%
6M Prestazione:
+189.67%
1 anno Prestazione:
+210.44%
Intervallo 1D:
$97.10
$104.38
Intervallo di 1 settimana:
$97.10
$112.42
Portata 52W:
$20.44
$118.84
Grail Inc Stock (GRAL) Company Profile
Nome
Grail Inc
Settore
Industria
Telefono
(833) 694-2553
Indirizzo
1525 O'BRIEN DRIVE, MENLO PARK
Confronta GRAL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
97.82 | 3.94B | 117.67M | -1.88B | -621.36M | -60.54 |
|
TMO
Thermo Fisher Scientific Inc
|
578.61 | 222.48B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
218.89 | 155.25B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
670.46 | 54.04B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
230.15 | 40.13B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
133.85 | 37.78B | 6.95B | 1.30B | 1.15B | 4.5696 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-02 | Ripresa | Morgan Stanley | Equal-Weight |
| 2025-11-12 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-04-21 | Iniziato | Canaccord Genuity | Buy |
| 2024-11-27 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-10-17 | Iniziato | Guggenheim | Neutral |
Mostra tutto
Grail Inc Borsa (GRAL) Ultime notizie
Samsung and GRAIL Announce Strategic Collaboration To Bring GRAIL’s Galleri® Multi-Cancer Early Detection Test to Asia - samsung.com
GRAIL, Inc.'s (NASDAQ:GRAL) Institutional Investors Lost 13% Over the Past Week but Have Profited From Longer-term Gains - 富途牛牛
GRAIL Submits FDA Premarket Approval Application for Galleri Multi-Cancer Early Detection Blood Test - Patient Care Online
GRAIL Submits FDA PMA for Galleri Multi-Cancer Early Detection Test - Yahoo Finance
GRAIL (GRAL) Is Down 13.0% After Final PMA Module Filing for Galleri Multi-Cancer Test - Sahm
Trifecta Capital Advisors LLC Purchases 10,250 Shares of GRAIL, Inc. $GRAL - MarketBeat
Grail Submits Premarket Approval Application to FDA for Multi-Cancer Early Detection Test - marketscreener.com
Grail raised to Buy at Guggenheim on potential of Galleri - MSN
Grail submits FDA premarket approval appplication for Galleri - TipRanks
GRAIL's Galleri multi-cancer test takes key step toward FDA approval - Stock Titan
GRAIL Submits FDA Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test - Chartmill
Assessing GRAIL (GRAL) Valuation After Analyst Upgrades And Strong Recent Shareholder Returns - simplywall.st
GRAIL Inc (GRAL) Trading Down 7.75% on Jan 28 - GuruFocus
Multi Cancer Early Detection Market Is Going to Boom |• GRAIL • Freenome • Thrive Earlier Detection - openPR.com
Why (GRAL) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Beyond The Numbers: 4 Analysts Discuss GRAIL Stock - Benzinga
GRAIL Inc.: Strong Galleri Momentum and Upcoming Regulatory Catalysts Support Buy Rating and $105 Target - TipRanks
Guggenheim Raises GRAIL (GRAL) Price Target to $130 | GRAL Stock News - GuruFocus
Why GRAIL Inc Shares Are Surging Higher Now - TipRanks
Grail price target raised to $130 from $100 at Guggenheim - TipRanks
How Is The Market Feeling About GRAIL Inc? - Benzinga
Canaccord Genuity reiterates Buy rating on GRAIL stock with $105 target - Investing.com Nigeria
GRAIL Stock (-9.6%) : Guidance Disappoints + Valuation Reset - Trefis
GRAIL (NASDAQ:GRAL) Trading Down 7.7%Here's Why - MarketBeat
Why GRAIL Inc Shares Are Sliding Despite Guidance - TipRanks
No News JSON Data Available - StocksToTrade
GRAIL stock jumps as Galleri outlook and FDA filing timeline come back into focus - TechStock²
Here's Why This Exciting Healthcare Stock Popped 13% Today - AOL.com
Here's Why This Exciting Healthcare Stock Popped 13% Today - The Motley Fool
GRAIL (NASDAQ:GRAL) Reaches New 12-Month HighWhat's Next? - MarketBeat
## Key Takeaways - timothysykes.com
Grail stock hits all-time high at 116.28 USD - Investing.com
GRAIL, Inc. (GRAL): A Bull Case Theory - MSN
Does GRAIL’s 2025 Revenue Guidance Clarify Its Long-Term Growth Narrative For Investors (GRAL)? - simplywall.st
GRAIL (NASDAQ:GRAL) Trading Up 8.4%Still a Buy? - MarketBeat
GRAL Shares Surge as Market Awaits Major Strategic Announcements - StocksToTrade
GRAIL Inc (GRAL) Shares Up 4.37% on Jan 20 - GuruFocus
GRAIL Inc.Illumina's Divested Holy Grail (NASDAQ:GRAL) - Seeking Alpha
Illumina: What Is Next In This Sequence? (NASDAQ:ILMN) - Seeking Alpha
This company says it has produced the Holy Grail of batteries - The Washington Post
A Look At GRAIL’s Valuation As New 2025 Guidance And Morgan Stanley Coverage Shape Expectations - simplywall.st
Understanding Momentum Shifts in (GRAL) - Stock Traders Daily
Lobbying Update: $60,000 of GRAIL INC. lobbying was just disclosed - Quiver Quantitative
GRAIL (NASDAQ:GRAL) Trading Down 5.7%Time to Sell? - MarketBeat
GRAIL Inc (GRAL) Shares Gap Down to $99.95 on Jan 15 - GuruFocus
GRAIL (GRAL) Price Target Increased by 46.34% to 91.80 - MSN
Market Fear: Is GRAIL LLC likely to announce a buybackM&A Rumor & High Win Rate Trade Alerts - baoquankhu1.vn
Canaccord Genuity reiterates Buy rating on GRAIL stock after strong results - Investing.com Nigeria
Does Morgan Stanley’s Hold on GRAIL (GRAL) Reframe Expectations for Galleri’s Path to Profitability? - simplywall.st
Illumina Produces Midteens Earnings Growth in 2025, Distancing Itself From the Grail Debacle - Morningstar
GRAIL Surges as Canaccord Genuity Sets Ambitious $105 Price Target Following Robust 2025 Growth - FinancialContent
Grail Inc Azioni (GRAL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.19%
0.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):